Axisymmetric bis-tridentate Ir(III) photoredox catalysts for anticancer phototherapy under hypoxia.

Li WeiRajesh KushwahaAnyi DaoZhongxian FanSamya Banerjee Huaiyi Huang

Published in: Chemical communications (Cambridge, England) (2023)

A novel axisymmetric bis-tridentate Ir(III) photocatalyst (Ir3) with synergetic type I/II photosensitization and photocatalytic activity was reported. Ir3 exhibited high photocytotoxicity toward drug-resistant cancer cells under normoxia and hypoxia. The photoactivated anticancer mechanism of Ir3 were investigated in detail. Overall, this new photo-redox catalyst can overcome hypoxia and drug resistance-related problems in clinical anticancer therapy.

Keyphrases

drug resistant
visible light
highly efficient
ionic liquid
multidrug resistant
endothelial cells
acinetobacter baumannii
mental health
reduced graphene oxide
bone marrow
mesenchymal stem cells
smoking cessation
electron transfer
replacement therapy